Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

NCT03364036 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Mavenclad®

Sponsor

Merck KGaA, Darmstadt, Germany